Navigation Links
FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
Date:2/19/2008

, including statements with respect to the development and commercialization of levocetirizine. Among the factors that could cause actual results to differ materially from those indicated by such forward-looking statements are: the results of research, development and clinical trials; the timing and success of submission, acceptance, and approval of regulatory filings; the time and resources UCB devotes to the development and commercialization of levocetirizine and the scope of UCB's patents and the patents of others.

Sanofi-aventis Forward-Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include product development, product potential projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future events, operations, products and services, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans" and similar expressions. Although sanofi-aventis' management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of sanofi-aventis, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMEA
'/>"/>

SOURCE sanofi-aventis
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
6. Tourtellotte Solutions Blazes Trail with New Release of Clinical Trial Supply Chain Simulator
7. Image Solutions, Inc. Acquires Zurich Biostatistics, Inc.
8. Data from Three Clinical Trials for Perforomist(TM) Inhalation Solution to be Presented at CHEST 2007 on October 24, 2007
9. Studies Show Body Mass Index Has No Effect on Resolution and Healing of GERD Symptoms
10. Facet Solutions Enjoys Continued Clinical Success With the Anatomic Facet Replacement System (AFRS(TM))
11. Facet Solutions AFRS(TM) Demonstrates Biomechanical Advantages Over Dynamic Stabilization in Independent Testing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... GARDENS, Fla. , Jan. 15, 2014  In an unprecedented effort ... and TB in ambulances and other transport vehicles, an advanced and ... by rescue personnel for the first time. In ... contact with these deadly pathogens, West Palm Beach ...
(Date:1/15/2014)... 15, 2014 The Cadence Fitness & Health Center ... the Medical Fitness Association, a non-profit organization assisting medically ... potential. The Cadence Fitness & Health Center is the ... second in the Chicagoland area. "The certification ...
(Date:1/15/2014)... 2014  Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ... by its indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ("Purchaser"), ... of Solta Medical, Inc. (NASDAQ: SLTM ) ...
Breaking Medicine Technology:Superbugs No Longer Ride In Rescue Vehicles 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3
(Date:4/24/2014)... better understanding of drug interactions, which are a major ... two or more medications are taken at the same ... the other. Similarly, one drug may magnify the ... major cause of illness and hospitalization. However, there ... drug studies in humans. Limits come in part ...
(Date:4/24/2014)... lenses coated with an antimicrobial peptide could help to lower ... Optometry and Vision Science , official journal ... journal is published by Lippincott Williams & Wilkins , ... in animals and now humans support the biocompatibility and safety ... the new research by Debarun Dutta, B.Optom, of The University ...
(Date:4/24/2014)... April 28, the Center for BrainHealth will bring ... most pressing brain-related challenges at its inaugural Brain ... and Regeneration." Featured speakers will include Dr. Sandra ... Center for BrainHealth, U.S. Senator Chuck Grassley (R-IA), ... Deputy Assistant Secretary for Policy and Early Learning, ...
(Date:4/24/2014)... corresponding terminology, and the relevance of palliation in ... on randomized controlled trials (RCTs). This is the ... for Quality and Efficiency in Health Care (IQWiG), ... , Together with external experts, IQWiG analysed studies ... cancer, malignant melanoma, and pancreatic cancer. For this ...
(Date:4/24/2014)... It is better to give than to receive at ... new study suggests. , The study found that 15- and ... their money to family members, are less likely to become ... risks or keeping the money for themselves. , The researchers ... Academy of Sciences . , The study focused on the ...
Breaking Medicine News(10 mins):Health News:Large-scale identification and analysis of suppressive drug interactions 2Health News:Study supports safety of antimicrobial peptide-coated contact lenses 2Health News:Study supports safety of antimicrobial peptide-coated contact lenses 3Health News:Inaugural Brain Health Summit focuses on brain resilience and regeneration 2Health News:Palliation is rarely a topic in studies on advanced cancer 2Health News:Palliation is rarely a topic in studies on advanced cancer 3Health News:Study: Altruistic adolescents less likely to become depressed 2
... NEW YORK, May 12 portionpals(R), an innovative,weight-loss tool ... million sales mark,this past Saturday, May 10th, in less ... the "diet" alternative among consumers,looking for a healthy way ... is,gaining market share in a multi-billion dollar industry with ...
... serious, but genetics could bring screening test or treatment , , ... COMT, already known for its role in schizophrenia, also plays ... preeclampsia, a new study finds. , Although the current study ... the findings could be used as a test to identify ...
... MEDX ) announced today its financial results for the quarter ... or $1.19 per share, from Medarex,s,sale of 2.5 million shares ... the quarter ended March 31, 2008, was $103.3 million, or,$0.81 ... million, or $0.88,per share for the same period in 2007. ...
... DUBLIN, Ohio, May 12 On May 30, 2008, ... Chicago, New York,Philadelphia, Cleveland, Madison, Atlanta, Seattle, Dearborn, and ... Abigail Alliance, A Right,To Live, and the Sarcoma Foundation ... out and attend a protest., 1 in 6 ...
... MedCath Corporation,(Nasdaq: MDTH ), a health ... predominantly the diagnosis and treatment of cardiovascular,disease, today ... currently Interim Chief Financial Officer, has been named,Senior ... his new role, Art will continue to oversee ...
... YORK, May 12 InfuSystem Holdings, Inc.,(OTC Bulletin ... infusion pumps and associated clinical services, today announced,financial ... first quarter of,2008., Mr. Steve Watkins, chief ... of our first full quarter of operations as ...
Cached Medicine News:Health News:Diet Industry Newcomer Hits the 1 Million Unit Mark 2Health News:Gene May Be Key to Pregnancy Complication 2Health News:Gene May Be Key to Pregnancy Complication 3Health News:Medarex Announces 2008 First Quarter Financial Results 2Health News:Medarex Announces 2008 First Quarter Financial Results 3Health News:Medarex Announces 2008 First Quarter Financial Results 4Health News:Medarex Announces 2008 First Quarter Financial Results 5Health News:Medarex Announces 2008 First Quarter Financial Results 6Health News:Medarex Announces 2008 First Quarter Financial Results 7Health News:Medarex Announces 2008 First Quarter Financial Results 8Health News:FDA Says, 'Wait' To Dying Men; Coast-To-Coast Prostate Cancer Demonstrations on May 30th in Protest of FDA Failure to Approve Safe, Effective Immunotherapy 2Health News:FDA Says, 'Wait' To Dying Men; Coast-To-Coast Prostate Cancer Demonstrations on May 30th in Protest of FDA Failure to Approve Safe, Effective Immunotherapy 3Health News:MedCath Names Parker to New Finance Post 2Health News:InfuSystem Holdings Provides Business Update and Comments on First Quarter 2008 Financial Results 2Health News:InfuSystem Holdings Provides Business Update and Comments on First Quarter 2008 Financial Results 3Health News:InfuSystem Holdings Provides Business Update and Comments on First Quarter 2008 Financial Results 4Health News:InfuSystem Holdings Provides Business Update and Comments on First Quarter 2008 Financial Results 5Health News:InfuSystem Holdings Provides Business Update and Comments on First Quarter 2008 Financial Results 6Health News:InfuSystem Holdings Provides Business Update and Comments on First Quarter 2008 Financial Results 7Health News:InfuSystem Holdings Provides Business Update and Comments on First Quarter 2008 Financial Results 8Health News:InfuSystem Holdings Provides Business Update and Comments on First Quarter 2008 Financial Results 9
Midstream Catch Kits...
... a handheld, noninvasive ultrasound instrument that measures ... so any staff member can scan patients ... from exams and print BVI 6100 exam ... log on to ScanPoint®, Diagnostic Ultrasound's innovative ...
... The Mobile BladderScan® BVI 6400 calculates ... ultrasound technology. V-MODE® ultrasound is accurate, ... seconds, the BladderScan® measures ultrasonic reflections ... planes, creates a 3-dimensional image of ...
... EXP Injectable Bulking Agent is ... suspended in a water-based carrier ... Agent is indicated for the ... stress urinary incontinence due to ...
Medicine Products: